AHRQ CER review for pediatric testing of musculoskeletal complaints
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research and Quality is taking comments through April 19 on five key questions on the comparative effectiveness of antinuclear antibody, rheumatoid factor and citric citrullinated peptide testing to evaluate musculoskeletal complaints in children. AHRQ wants more data on the sensitivity and specificity of tests that are used to help identify juvenile idiopathic arthritis and systemic lupus erythematosus